The risk model construction of the genes regulated by H3K36me3 and H3K79me2 in breast cancer

Ling-Yu Wang; Lu-Qiang Zhang; Qian-Zhong Li; Hui Bai

doi:10.52601/bpr.2023.220022

Volume 9 Issue 1

Feb. 2023

Turn off MathJax

Article Contents

Article Navigation > Biophysics Reports > 2023 > 9(1): 45-56

Ling-Yu Wang, Lu-Qiang Zhang, Qian-Zhong Li, Hui Bai. The risk model construction of the genes regulated by H3K36me3 and H3K79me2 in breast cancer. Biophysics Reports, 2023, 9(1): 45-56. doi: 10.52601/bpr.2023.220022

Citation:

Ling-Yu Wang, Lu-Qiang Zhang, Qian-Zhong Li, Hui Bai. The risk model construction of the genes regulated by H3K36me3 and H3K79me2 in breast cancer. Biophysics Reports, 2023, 9(1): 45-56. doi: 10.52601/bpr.2023.220022

Citation:

PDF (4211 KB)

The risk model construction of the genes regulated by H3K36me3 and H3K79me2 in breast cancer

doi: 10.52601/bpr.2023.220022

Ling-Yu Wang¹,
Lu-Qiang Zhang^{1
,
,},
Qian-Zhong Li^{1, 2
,
,},
Hui Bai¹

1.
Laboratory of Theoretical Biophysics, School of Physical Science and Technology, Inner Mongolia University, Hohhot 010021, China
2.
The State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, Hohhot 010070, China

More Information

Corresponding author: 111989025@imu.edu.cn (L.-Q. Zhang); qzli@imu.edu.cn (Q.-Z. Li)
Received Date: 03 September 2022
Accepted Date: 23 February 2023

Available Online: 07 June 2023

Publish Date: 28 February 2023

Abstract

Abstract

Abnormal histone modifications (HMs) can promote the occurrence of breast cancer. To elucidate the relationship between HMs and gene expression, we analyzed HM binding patterns and calculated their signal changes between breast tumor cells and normal cells. On this basis, the influences of HM signal changes on the expression changes of breast cancer-related genes were estimated by three different methods. The results showed that H3K79me2 and H3K36me3 may contribute more to gene expression changes. Subsequently, 2109 genes with differential H3K79me2 or H3K36me3 levels during cancerogenesis were identified by the Shannon entropy and submitted to perform functional enrichment analyses. Enrichment analyses displayed that these genes were involved in pathways in cancer, human papillomavirus infection, and viral carcinogenesis. Univariate Cox, LASSO, and multivariate Cox regression analyses were then adopted, and nine potential breast cancer-related driver genes were extracted from the genes with differential H3K79me2/H3K36me3 levels in the TCGA cohort. To facilitate the application, the expression levels of nine driver genes were transformed into a risk score model, and its robustness was tested via time-dependent receiver operating characteristic curves in the TCGA dataset and an independent GEO dataset. At last, the distribution levels of H3K79me2 and H3K36me3 in the nine driver genes were reanalyzed in the two cell lines and the regions with significant signal changes were located.
- Breast cancer,
- Gene expression,
- H3K79me2,
- H3K36me3,
- Driver genes

Ling-Yu Wang, Lu-Qiang Zhang, Qian-Zhong Li and Hui Bai declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by any of the authors.

FullText(HTML)

References(45)

References

Albanese CM, Suttapitugsakul S, Perati S, McGown LB (2018) A genome-inspired, reverse selection approach to aptamer discovery. Talanta 177: 150−156 doi: 10.1016/j.talanta.2017.08.093

Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, Dekan G, Vogl S, Kubista E, Heider KH, Stratowa C, Schreiber M, Sommergruber W (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64: 844−856 doi: 10.1158/0008-5472.CAN-03-2361

Anderson LN, Cotterchio M, Cole DE, Knight JA (2011) Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidem Biomar 20: 1708−1717 doi: 10.1158/1055-9965.EPI-11-0300

Audia JE, Campbell RM (2016) Histone modifications and cancer. Cold Spring Harb Perspect Biol 8: a019521. https://doi.org/10.1101/cshperspect.a019521

Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, Nwosu ZC, Zhang L, Czerwonka A, Pawłowska A, Xia H, Li J, Liao P, Yu J, Vatan L, Szeliga W, Wei S, Grove S, Liu JR, McLean K, Cieslik M, Chinnaiyan AM, Zgodziński W, Wallner G, Wertel I, Okła K, Kryczek I, Lyssiotis CA, Zou W (2020) Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature 585: 277−282 doi: 10.1038/s41586-020-2682-1

Duan C, Wang H, Chen Y, Chu P, Xing T, Gao C, Yue Z, Zheng J, Jin M, Gu W, Ma X (2018) Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy. Cancer Cell Int 18: 21. https://doi.org/10.1186/s12935-018-0521-3

Eroglu E, Schell JP, Chien KR (2021) PHF7 directs cardiac reprogramming. Nat Cell Biol 23: 440−442 doi: 10.1038/s41556-021-00684-z

Feng ZX, Li QZ, Meng JJ (2019) Modeling the relationship of diverse genomic signatures to gene expression levels with the regulation of long-range enhancer-promoter interactions. Biophys Rep 5: 123−132 doi: 10.1007/s41048-019-0089-z

Harbeck N, Gnant M (2017) Breast cancer. Lancet 389: 1134−1150 doi: 10.1016/S0140-6736(16)31891-8

He J, Li CF, Lee HJ, Shin DH, Chern YJ, Pereira De Carvalho B, Chan CH (2021) MIG-6 is essential for promoting glucose metabolic reprogramming and tumor growth in triple-negative breast cancer. EMBO Rep 22: e50781. https://doi.org/10.15252/embr.202050781

Hinshelwood RA, Clark SJ (2008) Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med 86: 1315−1328 doi: 10.1007/s00109-008-0386-3

Jin W, Li QZ, Liu Y, Zuo YC (2020) Effect of the key histone modifications on the expression of genes related to breast cancer. Genomics 112: 853−858 doi: 10.1016/j.ygeno.2019.05.026

Jing HY, Liaw L, Friesel R, Vary C, Hua S, Yang X (2016) Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells. Cancer Cell Int 16: 19. https://doi.org/10.1186/s12935-016-0292-7

Kelemen LE, Wang XS, Fredericksen ZS, Pankratz VS, Pharoah PDP, Ahmed S, Dunning AM, Easton DF, Vierkant RA, Cerhan JR, Goode EL, Olson JE, Couch FJ (2009) Genetic variation in the chromosome 17q23 amplicon and breast cancer risk. Cancer Epidem Biomar 18: 1864−1868 doi: 10.1158/1055-9965.EPI-08-0486

Lee YT, Tan YJ, Falasca M, Oon CE (2020) Cancer-associated fibroblasts: epigenetic regulation and therapeutic intervention in breast cancer. Cancers 12: 2949. https://doi.org/10.3390/cancers12102949

Li T, Liu Q, Garza N, Kornblau S, Jin VX (2018) Integrative analysis reveals functional and regulatory roles of H3K79me2 in mediating alternative splicing. Genome Med 10: 30. https://doi.org/10.1186/s13073-018-0538-1

Liu H, Chen Y, Lv J, Liu H, Zhu R, Su J, Liu X, Zhang Y, Wu Q (2013) Quantitative epigenetic co-variation in CpG islands and co-regulation of developmental genes. Sci Rep 3: 2576. https://doi.org/10.1038/srep02576

Messier TL, Gordon JA, Boyd JR, Tye CE, Browne G, Stein JL, Lian JB, Stein GS (2016) Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes. Oncotarget 7: 5094−5109 doi: 10.18632/oncotarget.6922

Mojica CAR, Ybañez WS, Olarte KCV, Poblete ABC, Bagamasbad PD (2020) Differential glucocorticoid-dependent regulation and function of the ERRFI1 gene in triple-negative breast cancer. Endocrinology 161: bqaa082. https://doi.org/10.1210/endocr/bqaa082

Morgan MAJ, Shilatifard A (2020) Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation. Nat Genet 52: 1271−1281 doi: 10.1038/s41588-020-00736-4

Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621−628 doi: 10.1038/nmeth.1226

Nair VS, El Salhat H, Taha RZ, John A, Ali BR, Elkord E (2018) DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics 10: 78. https://doi.org/10.1186/s13148-018-0512-1

Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, Van der Vegt B, Overmoyer B, De Vries EG, Schröder CP (2015) Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. Pharmacol Ther 147: 63−79 doi: 10.1016/j.pharmthera.2014.11.004

Pasculli B, Barbano R, Parrella P (2018) Epigenetics of breast cancer: biology and clinical implication in the era of precision medicine. Semin Cancer Biol 51: 22−35 doi: 10.1016/j.semcancer.2018.01.007

Pathak GP, Shah R, Kennedy BE, Murphy JP, Clements D, Konda P, Giacomantonio M, Xu Z, Schlaepfer IR, Gujar S (2018) RTN4 knockdown dysregulates the AKT pathway, destabilizes the cytoskeleton, and enhances paclitaxel-induced cytotoxicity in cancers. Mol Ther 26: 2019−2033 doi: 10.1016/j.ymthe.2018.05.026

Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME (2005) GREB1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92: 141−149 doi: 10.1007/s10549-005-1483-4

Rahman MM, Brane AC, Tollefsbol TO (2019) MicroRNAs and epigenetics strategies to reverse breast cancer. Cells 8: 1214. https://doi.org/10.3390/cells8101214

Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16: 103−119 doi: 10.1517/14728222.2011.645805

Schubeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, van Leeuwen F, Gottschling DE, O'Neill LP, Turner BM, Delrow J, Bell SP, Groudine M (2004) The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 18: 1263−1271 doi: 10.1101/gad.1198204

Shivakumar M, Lee Y, Bang L, Garg T, Sohn KA, Kim D (2017) Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer. BMC Med Genomics 10: 30. https://doi.org/10.1186/s12920-017-0269-y

So WK, Cheng JC, Liu Y, Xu C, Zhao J, Chang VT, Leung PC (2016) Sprouty4 mediates amphiregulin-induced down-regulation of E-cadherin and cell invasion in human ovarian cancer cells. Tumour Biol 37: 9197−9207 doi: 10.1007/s13277-016-4790-y

Su WX, Zhang DM, Zhang Q, Li QZ (2021) Study on the spatial distribution patterns of histone modifications in Hippo pathway genes. Biophys Rep 7: 71−79 doi: 10.52601/bpr.2021.200042

Vanas V, Mühlbacher E, Kral R, Sutterlüty-Fall H (2014) Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines. Tumour Biol 35: 4447−4456 doi: 10.1007/s13277-013-1587-0

Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537−549 doi: 10.1038/nrc2694

Wagner GP, Kin K, Lynch VJ (2012) Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples. Theory Biosci 131: 281−285 doi: 10.1007/s12064-012-0162-3

Wang J, Thompson B, Ren C, Ittmann M, Kwabi-Addo B (2006) Sprouty4, a suppressor of tumor cell motility, is downregulated by DNA methylation in human prostate cancer. Prostate 66: 613−624 doi: 10.1002/pros.20353

Williams GH, Stoeber K. (2012) The cell cycle and cancer. J Pathol 226: 352−364 doi: 10.1002/path.3022

Xiao C, Fan T, Tian H, Zheng YJ, Zhou Z, Li SF, Li CX, He J (2021) H3K36 trimethylation-mediated biological functions in cancer. Clin Epigenetics 13: 199. https://doi.org/10.1186/s13148-021-01187-2

Xu J, Keeton AB, Wu L, Franklin JL, Cao X, Messina JL (2005) Gene 33 inhibits apoptosis of breast cancer cells and increases poly(ADP-ribose) polymerase expression. Breast Cancer Res Tr 91: 207−215 doi: 10.1007/s10549-005-1040-1

Yu GC, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. Omics 16: 284−287 doi: 10.1089/omi.2011.0118

Zhang LQ, Fan GL, Liu JJ, Liu L, Li QZ, Lin H (2021a) The impact of gene-body H3K36me3 patterns on gene expression level changes in chronic myelogenous leukemia. Gene 802: 145862. https://doi.org/10.1016/j.gene.2021.145862

Zhang LQ, Li QZ (2017) Estimating the effects of transcription factors binding and histone modifications on gene expression levels in human cells. Oncotarget 8: 40090−40103 doi: 10.18632/oncotarget.16988

Zhang LQ, Liu JJ, Li L, Fan GL, Li YN, Li QZ (2021b) Identification of key histone modifications and their regulatory regions on gene expression level changes in chronic myelogenous leukemia. Front Cell Dev Biol 8: 621578. https://doi.org/10.3389/fcell.2020.621578

Zhang LQ, Yang H, Liu JJ, Zhang LR, Hao YD, Guo JM, Lin H (2022) Recognition of driver genes with potential prognostic implications in lung adenocarcinoma based on H3K79me2. Comput Struct Biotec 20: 5535−5546 doi: 10.1016/j.csbj.2022.10.004

Zhang Y, Liu H, Lv J, Xiao X, Zhu J, Liu X, Su J, Li X, Wu Q, Wang F, Cui Y (2011) QDMR: a quantitative method for identification of differentially methylated regions by entropy. Nucleic Acids Res 39: e58. https://doi.org/10.1093/nar/gkr053

Supplements(0)

Relative Articles

Cited By

Proportional views